|Day Low/High||11.46 / 11.88|
|52 Wk Low/High||9.70 / 24.93|
Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.
Levi & Korsinsky announces it has commenced an investigation of Endo International plc (NASDAQ: ENDP) concerning possible violations of federal securities laws.
The Law Firm of Arons & Arons, LLC. has initiated an investigation of Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) on behalf of the company's investors for possible violations of federal securities...
Levi & Korsinsky announces it has commenced an investigation of Endo International plc (NASDAQ:ENDP) concerning possible violations of federal securities laws.
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) concerning the Company and its officers' possible violations of federal...
This marks the first time that the FDA is seeking to remove an opioid pain medication from the market due to the public health consequences of abuse.
Uber's first quarter loss was less than the $991 million loss reported 3 months ago.
Ohio Attorney General Mike DeWine claims the companies weren't honest with doctors about the risks associated with the painkillers.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
The investigation is in relation to drug pricing in the pharmaceutical industry.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
Biogen's new spine disease drug outperformed expectations during its commercial debut.
Organovo, Endo and Omeros were among the biotech stock moves in premarket trading on Thursday.
Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.
Endo International slipped 5% ahead of market's open Friday.
An FDA advisory committee has found that risks of Endo International's pain drug Opana ER now overshadow the drug's benefits.